The Life Sciences team advised Absci Corporation (Nasdaq: ABSI) on the closing of its underwritten public offering of 19,205,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $86.4 million. All of the shares in the offering were sold by Absci.

Absci Corporation is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. The company’s Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit.

The Goodwin team was led by Kingsley Taft, Maggie Wong, Alicia Tschirhart, Kathryn Clerici and Manjinder Kaur and included Alex Varond (FDA/Regulatory), Dan Karelitz and Gregg Coughlin (Tax); and Brad Weber (Opinions).

For additional details on the offering, please read the press release.